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Abstract Polymorphonuclear leukocytes (PMNs) have been implicated in the pathogenesis of COPD, partly because
of the release of oxidants, like superoxide anion (SA).The goal of this study was tomeasure the spontaneous and stimu-
lated release of SAby peripheral PMNin stable COPD comparedwith healthy controls. Seventeen patientswith stable
moderate COPD and17 healthy age-matched controls were included. SA release fromperipheral PMN wasmeasured
spectrophotometrically as the superoxide dismutase (SOD) inhibitable reduction of cytochrome c. PMNswere stimu-
latedwith phorbolmyristate acetate (PMA,1and10 ng/ml), diesel exhaust particles (DEPs), carbonblack (CB) and ultra-
fine CB (ufCB,125, 250 and 500 mg/ml).The spontaneous SArelease (PMA-0) betweenpatients andcontrolsubjectswas
not significantlydifferent.After stimulationwith PMA,SArelease increasedinbothpatients andcontrols.The SArelease
didnotincrease after stimulationwithDEPandCBinpatientsnorincontrols.Therewasonlyanincrease after stimulation
withufCB inthe patientgroup.The increased SArelease in COPD patients after stimulationwithufCBmay suggestthat
PMNof COPD patients aremoreproneto stimulation andthatthe smallerparticle size of ufCBmightbe a crucial factor.
r 2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1461, available online at http://www.sciencedirect.com
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Polymorphonuclear leukocytes (PMNs) have been impli-
cated in the pathogenesis of COPD.They are involved in
the in£ammatory process, re£ected by an increased
number of neutrophils in sputum, bronchoalveolar lavage
£uid (BAL £uid) and bronchial biopsies in smokers and
COPD patients (1^5). In addition, a large pool of PMNs
is presentwithin themicrovessels of the lung (6).
Following a stimulus (e.g. infection, injury, inhalation
of smoke and particulate matter), PMNs migrate from
the peripheral blood into the extravascular space. SomeReceived 28 May 2002, accepted in revised form19 September 2002.
Correspondence should be addressed to:Dr. P. L.M.LWielders,
Department of Pulmonology,Catharina Hospital Eindhoven, POBox
1350, 5602 ZAEindhoven,The Netherlands.
E-mail: wendy@beurdenvan.myweb.nlmigrate to the lungs and through the endothelium into
the airway lumen,where theyperform their ‘task’ofpha-
gocytosis and destruction of an intruding organism or
particle (7,8). Bosken et al. showed that the number of
submucosal PMNs is related to the amount smoked (4).
A possible mechanism is that alveolar macrophages of
smokers release a chemotactic factor for neutrophils (5).
Eventually, the accumulation and activation of PMN
mayresult in an adverse e¡ectof destruction of parench-
ymal tissue (i.e. development of emphysema), both
through proteolysis by the elastase released from the ly-
sosomal granules and the release of reactive oxygen-de-
rived species (ROS), like superoxide anion (SA) and
hydrogen peroxide (H2O2). In vivo evidence for an in-
creased oxidative burden has been provided by Dekhuij-
zen et al. who showed that patients with stable COPD
had higher concentrations of H2O2 in exhaled breath
402 RESPIRATORYMEDICINEcondensate than healthy control subjects (9). The
production of H2O2 was further increased during ex-
acerbations.
The increased oxidativeburden is notonlydetermined
by an increase in the number of in£ammatory cells like
PMN, but also by an increased production of oxidants
per cell (10). In healthy smokers, PMN showed increased
production of oxidants (11). In COPD patients,Teramoto
et al. showed that spontaneous production of oxidants
(SA) by PMNwas similar to normal subjects. In contrast,
Noguera et al. showed an increased production of oxi-
dants by PMN in COPD patients compared with smo-
kers with normal lung function (12,13). Two studies
showed that the production of oxidants by PMNwas in-
creased after stimulationwithphorbolmyristate acetate
(PMA) in COPD patients compared with healthy smo-
kers (12,13). The production was also higher in smokers
comparedwith non-smokers (11).
Elevated concentrations of respirable particulate [i.e.
¢neparticleswith a diameter less than10mmin diameter
(PM10)] havebeen implicatedin adversehealth e¡ects, in-
cluding COPD (14,15). Respirable particulates contain a
variety of toxic substances on their surface and arise
amongst others frommotor vehicle exhausts, especially
those emitted from diesel engines (16). These diesel ex-
haust particles (DEPs) contain both dust (elemental car-
bon), traces of heavy metals and organic components,
which both enhance production of ROS by alveolar
macrophages in vitro (17,18). In animal studies, intratra-
cheal instillation of DEP, carbon black (CB) and ultra¢ne
particulate (ufCB), caused an acute in£ammatory re-
sponse with an in£ux of PMN in alveolar air spaces and
interstitium (17^19). Respirable particulate can also be
used to stimulate PMN directly.
The e¡ects of stimulation with respirable particulate
on SA generation by PMN of COPD patients in vitro, are
not known.Therefore, the aim of the present study was
to compare the release of SA by peripheral PMN, both
spontaneously and after stimulation with PMA, DEP,CB
and ufCB between stable COPD patients and healthy
controls.
METHODS
Subjects
Seventeen patients diagnosed with (stable) COPD
according to the criteria of the ERS (20) participated in
this study. Inclusion criteria were: age o75 years,
current or ex-smoker, forced expiratory volume in 1s
(FEV1) between o70 % of predicted or FEV1/FVC o60
%ofpredicted andreversibility less than15%ofpredicted
after inhalation of 400mg salbutamol or 80mg ipratro-
pium bromide. Further, 17 healthy age-matched control
subjects were recruited. Exclusion criteria for both
healthy controls and patients were a history of asthma,allergy, atopic constitution, known a1-proteinase
inhibitor de¢ciency or other pulmonary diseases, an
exacerbation or cold within the previous 8 weeks
and use of supplemental dietary anti-oxidants, vitamins
or N-acetylcystein. Both control subjects and
patients were considered to be ex-smokers if they had
discontinued smoking for at least 1 year prior to the
study. This study was approved by the local Ethical
Committee and informed consent was obtained from all
subjects.
Sample collection andpreparation
From each participant, 30ml of venous lithium-hepari-
nized blood was collected at16.00h. Samples were kept
overnight atroom temperature in the dark andprepared
according to Schalkwijk et al. (21) at the next day at
08.00h. After centrifugation, plasma was removed and
the bu¡y coat diluted1:1with physiological saline. Subse-
quently, 8ml of the plasma expander Plasmasteril was
added for sedimentation of the red cells.
The dextran plasma layer, containing plasma, lympho-
cytes and monocytes was collected and 7ml of Ficoll^
Hipaque solution (Pharmacia Biotech) with a density of
1.070g/ml was gently brought under the supernatant.
After centrifugation at room temperature during
20min at 2000 rpm, the plasma, lymphocytes, mono-
cytes and Ficoll^Hipaque were removed.The remaining
PMNs (density 1.080 g/ml) and erythrocytes (density
1.085 g/ml) in the cell pellet were suspended in 0.5ml
Hanks’ balanced salt solution (HBSS), and 13ml of aqua
purewas added to lysate the erythrocytes. After centri-
fugation at 41C during 5min at 1000 rpm, the cell pellet
was washedwith HBSS and ¢nally resuspended in 2.5ml
HBSS + 0.1% glucose.
The total and di¡erential cell counts were performed
with a standard hemocytometer.Viability was assessed
with the trypane blue exclusion test. The yield of PMN
was 30^40 % of the ¢rst sample with a high percentage
of neutrophils [mean (SEM) 92.4 % (0.37)] and a viability of
98% ormore.
Superoxide assay
SA releasewasmeasured spectrophotometrically as the
superoxide dismutase (SOD) inhibitable reduction of cy-
tochrome c, adapted for 96-well assay. Brie£y, 25ml of
HBSSwas added to 50ml of cytochrome c (640mM, Sig-
ma Chemicals), 25ml of SOD (2400U/ml, Sigma Chemi-
cals), 25ml of PMN suspension (4106/ml) and 50ml of
stimulus. For measurement of spontaneous release no
stimulus was added (PMA-0). For measurement of re-
lease, with (25ml) and without SOD and with (50ml)
and without cells, respectively, the ¢nal volume of
200ml was adjusted by adding HBSS.
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PMA (Phorbol 12-Myristate 13-Acetate, Sigma Chemi-
cals) was used as a stimulus in a concentration of 1 and
10ng/ml. Samples were incubated during 30min at
371C.The extinction was measured every 2min at 540
and 550nm using a Softmax 96-wells microplate reader.
Since there was a linear increase up to 30min for both
patients and healthy control subjects, the extinction
after 30min was used to calculate the concentration of
reduced cytochrome with a extinction coe⁄cient of
14 964 L/molcm.
DEP were collected from a 4kW diesel engine
(Yanmar, L90E, single cylinder). DEP, CB (acetylene
carbon black, Strem, Newsburyport, MA, U.S.A.)
and ufCB (Printex-90, diameter 20nm, surface area
33.7m2/g) were suspended in a ¢nal concentration
of 2 mg/ml phosphate-bu¡ered saline with 0.05%
Tween-80 after soni¢cation (MSE 100 Watt, Ultrasonic
Disintegrator 7100). Concentrations of 125, 250 and
500mg/ml were prepared. After stimulation, reaction
mixtures were incubated at 371C during 30min in a 24-
well plate.
Since addition of these stimuli caused a blackmixture,
measurement of extinction in time was not possible.
Therefore, samples were ¢ltered after 30min and ex-
tinction of the supernatantwasmeasured in the 96-well
microplate reader. The addition of 500mg/ml ufCB to
PMN probably caused a toxic reaction, since cells coagu-
lated and SA release was diminished.Therefore, the re-
sults of stimulation with 500mg/ml ufCB were
disregarded.
All samples were prepared in duplicate and the aver-
age value of the extinction was used for calculation. Fi-
nally, the SOD inhibitable reduction of cytochrome c
was calculated as the di¡erences in extinction between
thewells with andwithout SOD.TABLE 1. Characteristics studypopulation
Age (years)
FEV1 (% of predictedvalue)
Reversiblity (%)
Smokinghistory
Never smokers
Ex-smokers
Current smokers
Medication
ICS
Mean (SEM),FEV1 = forced expiratory volume in1second; re
applicable; ICS = inhaled corticosteroids.The results were expressed as the concentration of
reduced cytochrome c (nmol/ml) per 1  106 PMN per
30min.
Statistical analysis
Data are expressed as mean and standard error of the
mean (SEM). Di¡erences between patients with COPD
and healthy controls were analysed with the Student’s t-
test for independent samples. In£uence of smoking and
use ofmedicationwas analysedby analysis of covariance.
The slope of SA releasewith increasing concentration of
the stimuli was calculated with the linear regression
equation.Di¡erences in the slope between groups were
tested with the Mann-Whitney U-test using the indivi-
dual slopes. Di¡erences in the slopes within groups be-
tween similar stimuli were tested with the Friedman’s
analysis of variance for related samples. For all analyses,
a P-value less than 0.05 was considered signi¢cant.
RESULTS
Subjects
Seventeen COPD patients [mean FEV156.6 (4.9)% of pre-
dicted] and17 healthy controls were included (Table1).
Spontaneous SArelease
The spontaneous SA release (PMA-0) between patients
andcontrol subjectswas not signi¢cantlydi¡erent [mean
(SEM) 10.4 (1.4) vs. 10.3 (0.9) nmol/ml per 106 cells per
30min, P = 0.9] (Fig.1). Both smoking history and use of
medication didnot in£uence this result (data not shown).
The concentrations of DEP-0, CB-0 and ufCB-0 in the
patient group were 5.5 (0.9), 4.7 (0.8), and 4.2 (0.9) nmol/Healthycontrols
(N = 17)
Patients
(N = 17)
58 (2) 61 (2)
na 56.6 (4.9)
na 6.8 (1.1)
8 na
6 14
3 3
na 11
versibility = change in FEV1after 400 mg salbutamol; na = not
FIG. 1. Regression analysis of the concentration of PMA and
the concentration of reduced cytochrome c (nmol/ml) per 106
cells per 30min. Open circles (*) and error bars represent
mean (SEM) values of healthycontrols, solid circles (*) and error
bars representmean (SEM) values of patients.
FIG. 2. RegressionanalysisoftheconcentrationofDEPandthe
concentration of reduced cytochrome c (nmol/ml) per 106 cells
per 30min.Open circles (*) and error bars represent mean
(SEM) values of healthy controls, solid circles (*) and error bars
representmean (SEM) values of patients.
FIG. 3. Regression analysis of the concentration of CB and the
concentration of reduced cytochrome c (nmol/ml) per 106 cells
per 30min.Open circles (*) and error bars represent mean
(SEM) values of healthy controls, solid circles (*) and error bars
representmean (SEM) values of patients.
404 RESPIRATORYMEDICINEml 106 cells per 30min, respectively. In the healthy con-
trol group, the concentrations were 6.1 (0.8), 6.3 (0.7),
and 5.1 (0.7) nmol/ml 106 cells per 30min, respectively.
There were no signi¢cant di¡erences between patients
and healthy controls.
SArelease after stimulationwith PMA
The concentration of reduced cytochrome c per106 cells
per 30min after stimulation with 1ng/ml PMA (PMA-1)
and 10ng/ml PMA (PMA-10), increased signi¢cantly in
both patients and control subjects (Po0.01, Po0.01, re-
spectively) (Fig. 1). The mean concentration for PMA-1
was 24.84 (2.14) nmol/ml in patients and 27.9 (2.4) nmol/
ml in healthy controls (P = 0.34). For PMA-10, the mean
concentration was 45.1 (10.7) nmol/ml in patients and
45.3 (10.5) nmol/ml in healthy controls (P = 0.95).
No signi¢cant di¡erences in SA release nor in the
slope of increase in SA release were observed between
patients and control subjects. Smoking and the use of
ICS did not in£uence the results (data not shown).
SArelease after stimulationwith DEP,CB
and ufCB
The mean concentrations of reduced cytochrome c per
106 cells per 30min were similar in patients and healthy
controls, and didnot increase after stimulationwithDEP
(Fig. 2). After stimulation with CB a small increase in SA
releasewas observed in patients (Fig. 3).Yet, the slope of
increase in patients compared to controls was not signif-
icantlydi¡erent. In contrast, after stimulationwithufCB,
the slopes of increases were signi¢cantly di¡erent
(P = 0.02) (Fig. 4), i.e. an increased SA release in patientscomparedwith healthy controls. Again, smoking history
and the use of medication did not in£uence the results
with respect to DEP,CB and ufCB (data not shown).
DISCUSSION
The present study shows that the spontaneous release
of SAbyperipheral PMNinCOPD is not increased, com-
pared with healthy control subjects. After stimulation
with PMA, SA release was equally increased in both
COPD patients and healthy controls. After stimulation
with DEP and CB, the SA release was not increased in
patients nor in healthy controls. Only after stimulation
FIG. 4. Regression analysis of the concentration of ufCB and
the concentration of reduced cytochrome c (nmol/ml) per 106
cells per 30min. Open circles (*) and error bars represent
mean (SEM) values of healthycontrols, solid circles (*) and error
bars representmean (SEM) values of patients. *Po0.05
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COPD patients.
The results of the present study are in accordance
with the study of Teramoto et al., who also found no dif-
ference in spontaneous SA release between COPD pa-
tients and healthy controls (12). In contrast with Ludwig
et al., we observed no di¡erences between smoking and
non-smoking individuals (11). Postma et al. did not ¢nd a
di¡erence between smokers and ex-smokers with
chronic air£ow obstruction either (22).
In contrast to the present study, Noguera et al.
found that theproduction of ROSby PMNwas increased
in patients with COPD compared with healthy smokers
and non-smokers (13). However, they measured the
ROS production by the NADPH oxidase method and
not by SA release, which makes it di⁄cult to compare
results.
The use of ICS did not in£uence the results in the pre-
sent study.Verhoeven etal. also foundno e¡ect of inhaled
£uticasone propionate on superoxide production by pul-
monary cells retrieved with BAL in smoking COPD pa-
tients (23).
The failure to demonstrate di¡erences in spontaneous
SA release may suggest that the rest status of PMN in
stable COPD patients is not di¡erent from that in con-
trols.However, SA is onlyone of the oxidants that is pro-
duced by PMN, they also produce H2O2 and hydroxyl
radicals.
On the other hand, since formation of SA occurs prior
to other members of ROS, di¡erences in production of
other oxidants by PMN at rest between COPD patients
and healthy controls is very unlikely.The concentrations of DEP-0,CB-0 and ufCB-0 were
lower than the PMA-0 concentration. Since addition of
these stimuli caused a black mixture, measurement of
extinction in time was not possible. Therefore, samples
were analysed as described in themethod section, which
may explain the di¡erence in baseline value.
The data of thepresent study show that the release of
SA by PMN after stimulation with PMA is equally in-
creased in COPD patients and healthy controls. This is
in contrast with the data presented by several other in-
vestigators (12,13,22).
As mentioned above it is di⁄cult to compare our re-
sults with the results of Noguera et al. because of the dif-
ference in technique (13). The di¡erence in result
between our study and the study by Postma et al. could
be due to the time of reaction (22).They measured the
SA release after 15min of reaction while in the present
study the SA releasewasmeasured after 30min. Indeed,
the SA release was higher in our study using the same
PMA concentration. It is possible that the di¡erence in
SA release between PMNof COPD patients and healthy
controls present at15min disappears after a longer reac-
tion time. Teramoto et al. measured the SA release in
whole blood by chemiluminescence, since in their opi-
nion this is more likely to re£ect the in vivo situation (12).
Unfortunately, comparisonwith the current data is di⁄-
cult, primarily due to the di¡erent methodologies ap-
plied.
After stimulation with particles present in environ-
mental air (DEP,CB andufCB), SA release increased only
after ufCB stimulation in COPD patients.
To our knowledge, the e¡ect of stimulation with re-
spirable particles on PMN of COPD patients has not
been studied. It seems that exposure to DEP leads to ac-
cumulation of PMN, possibly through chemotactic
agents, but not to increased production of oxidants by
PMN (17,19).Only ufCB had an e¡ect on the production
of oxidants by PMN in COPD patients in this study.This
e¡ect may be explained by the smaller particle size of
ufCB. Several studies have shown that ufCB is more in-
£ammogenic than other particulates, probably caused
by increased surface area (24^27).The increasedproduc-
tion after stimulation with ufCB was not observed in
controls.Consequently, these data suggest a di¡erent re-
sponse of PMN to ultra¢ne particles in vitro. PMN of
COPD patients react stronger to stimulation with small
respirable particles, which suggests that there is a di¡er-
ence between PMN of COPD patients and PMN of
healthy persons.
In conclusion, the increased SA release in COPD pa-
tients with increasing concentrations of ufCB may sug-
gest that PMN in COPD patients are di¡erent from
PMNinhealthypersons.Furthermore, the smallerparti-
cle size of ufCB is a crucial factor in the stimulation of
PMN, since similar observationswere notmade after sti-
mulationwith DEP and CB.
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